COVID-19 in recent kidney transplant recipients
COVID-19 in recent kidney transplant recipients
复制标题
DOI：
10.1111/ajt.16120
复制
发表时间：
2020-06-28
影响因子：
8.8
通讯作者：
Raina, Shailesh
中科院分区：
文献类型：
--
作者：
Shingare, Ashay;Bahadur, Madan M.;Raina, Shailesh
随着2019冠状病毒病（COVID-19）大流行在地球仪蔓延，移植计划遭受挫折。我们报告了在活体供肾移植（LDKT）后1个月内首次感染COVID-19的经验。我们描述了2例LDKT受者，他们在移植后第19天和第7天被检测出严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染呈阳性。他们在诊断时症状轻微，没有发生任何呼吸系统并发症或同种异体移植物功能障碍。免疫抑制逐渐减弱;然而，鼻咽拭子实时逆转录聚合酶链反应（rRT-PCR）在较长时间内保持SARS-CoV-2阳性。与早期发表的近期死亡的COVID-19供体肾移植受者病例相比，年龄较小、无其他合并症以及用作诱导的抗胸腺细胞球蛋白（ATG）剂量较低可能有助于我们近期LDKT受者的良好结局。
As the coronavirus disease 2019 (COVID-19) pandemic spread across the globe, transplant programs suffered a setback. We report the first experience of COVID-19 infection within 1 month of living donor kidney transplant (LDKT). We describe 2 LDKT recipients who were detected positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at day 19 and day 7 posttransplant. They had minimal symptoms at diagnosis and did not develop any respiratory complications or allograft dysfunction. Immunosuppression was de-escalated; however, nasopharyngeal swab real-time reverse transcription polymerase chain reaction (rRT-PCR) remained positive for SARS-CoV-2 for a prolonged time. Younger age, absence of other comorbidities, and lower dose of anti-thymocyte globulin (ATG) used as induction possibly contributed to good outcome in our recent LDKT recipients compared with earlier published cases of recent deceased donor kidney transplant recipients with COVID-19.